Login Register Cart 0
Generic placeholder image

Current Medicinal Chemistry

Editor-in-Chief

ISSN (Print): 0929-8673
ISSN (Online): 1875-533X

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

WDFY3-AS2: A Potential Prognostic Factor and Therapeutic Target Related to Cancer

Author(s): Jie Mou, Jinlan Chen, Yinxin Wu, Yuequan He, Gang Zhou* and Chengfu Yuan*

Volume 30, Issue 25, 2023

Published on: 03 November, 2022

Page: [2814 - 2821] Pages: 8

DOI: 10.2174/0929867329666220909114416

Price: $65

conference banner
Abstract

Background: Abundant studies have shown that non-coding RNA is connected with tumor cell growth, migration and invasion. As a newly discovered non-coding RNA, WDFY3-AS2 has gradually emerged in the molecular mechanism of various tumors and has a potential prospect as a biological indicator of tumor prognosis. This review describes the pathophysiological mechanism and prognostic value of WDFY3-AS2 in different cancers.

Objective: This review reveals the changes and roles of WDFY3-AS2 in many tumors and cancers. The change of WDFY3-AS2 can be used as a cancer biomarker and plays an important role in improving tumor growth, migration and invasion. WDFY3-AS2 is unique because it can be considered a prognostic marker for many tumors and is of great significance for clinical diagnosis and treatment. WDFY3-AS2 shows the potential prognostic value and the prospect of therapeutic targets in various tumors.

Methods: PubMed reviewed the related literature to analyze and summarize the regulatory molecular mechanism of WDFY3-AS2 in various tumors and its value as a prognostic indicator.

Results: The abnormal expression of LncRNA WDFY3-AS2 in many cancers was connected with the poor prognosis of cancer patients, including diffuse glioma, hepatocellular carcinoma, ovarian cancer, esophageal cancer, triple-negative breast cancer, Clear Cell Renal Carcinoma, Esophageal squamous cell carcinoma, Lung adenocarcinoma, which participated in the recovery of orthodontic teeth. WDFY3-AS2 has revealed the cellular process of cancer cell growth, migration, and invasion.

Conclusion: The molecular mechanism of LncRNA WDFY3-AS2 regulating tumor specifically proves that WDFY3-AS2 has a good prospect in the biological index of prognosis or clinical treatment target of cancer patients.

Keywords: Long non-coding RNA, WDFY3-AS2, biological market, Prognosis, target, Treatment , mechanism

« Previous Next »
[1]
Ransohoff, J.D.; Wei, Y.; Khavari, P.A. The functions and unique features of long intergenic non-coding RNA. Nat. Rev. Mol. Cell Biol., 2018, 19(3), 143-157.
[http://dx.doi.org/10.1038/nrm.2017.104] [PMID: 29138516]
[2]
Dykes, I.M.; Emanueli, C. Transcriptional and post-transcriptional gene regulation by long Non-coding RNA. Genom. Proteom. Bioinform., 2017, 15(3), 177-186.
[http://dx.doi.org/10.1016/j.gpb.2016.12.005] [PMID: 28529100]
[3]
Chi, Y.; Wang, D.; Wang, J.; Yu, W.; Yang, J. Long non-coding RNA in the pathogenesis of cancers. Cells, 2019, 8(9), 1015.
[http://dx.doi.org/10.3390/cells8091015] [PMID: 31480503]
[4]
Wu, F.; Zhao, Z.; Chai, R.; Liu, Y.; Wang, K.; Wang, Z.; Li, G.; Huang, R.; Jiang, H.; Zhang, K. Expression profile analysis of antisense long non-coding RNA identifies WDFY3-AS2 as a prognostic biomarker in diffuse glioma. Cancer Cell Int., 2018, 18(1), 107.
[http://dx.doi.org/10.1186/s12935-018-0603-2] [PMID: 30069164]
[5]
Zhang, Z.; Wang, S.; Liu, W. EMT-related long non-coding RNA in hepatocellular carcinoma: A study with TCGA database. Biochem. Biophys. Res. Commun., 2018, 503(3), 1530-1536.
[http://dx.doi.org/10.1016/j.bbrc.2018.07.075] [PMID: 30037433]
[6]
Li, W.; Ma, S.; Bai, X.; Pan, W.; Ai, L.; Tan, W. Long noncoding RNA WDFY3-AS2 suppresses tumor progression by acting as a competing endogenous RNA of microRNA-18a in ovarian cancer. J. Cell. Physiol., 2020, 235(2), 1141-1154.
[http://dx.doi.org/10.1002/jcp.29028] [PMID: 31347170]
[7]
Rodrigues de Bastos, D.; Nagai, M.A. In silico analyses identify lncRNAs: WDFY3-AS2, BDNF-AS and AFAP1-AS1 as potential prognostic factors for patients with triple-negative breast tumors. PLoS One, 2020, 15(5), e0232284.
[http://dx.doi.org/10.1371/journal.pone.0232284] [PMID: 32401758]
[8]
Zhou, X.; Liu, G.; Xu, M.; Ying, X.; Li, B.; Cao, F.; Cheng, S.; Xiao, B.; Cheng, M.; Liang, L.; Jia, M.; Li, W.; Liu, J.; Li, Z. Comprehensive analysis of PTEN-related ceRNA network revealing the key pathways WDFY3-AS2-miR-21-5p/miR-221-3p/miR-222-3p - TIMP3 as potential biomarker in tumorigenesis and prognosis of kidney renal clear cell carcinoma. Mol. Carcinog., 2022, 61(5), 508-523.
[http://dx.doi.org/10.1002/mc.23396] [PMID: 35129856]
[9]
Zhang, Q.; Guan, F.; Fan, T.; Li, S.; Ma, S.; Zhang, Y.; Guo, W.; Liu, H. LncRNA WDFY3-AS2 suppresses proliferation and invasion in oesophageal squamous cell carcinoma by regulating miR-2355-5p/SOCS2 axis. J. Cell. Mol. Med., 2020, 24(14), 8206-8220.
[http://dx.doi.org/10.1111/jcmm.15488] [PMID: 32536038]
[10]
Ren, P.; Hong, X.; Chang, L.; Xing, L.; Zhang, H. USF1-induced overexpression of long noncoding RNA WDFY3-AS2 promotes lung adenocarcinoma progression via targeting miR-491-5p/ZNF703 axis. Mol. Carcinog., 2020, 59(8), 875-885.
[http://dx.doi.org/10.1002/mc.23181] [PMID: 32275336]
[11]
Wood, M.D.; Halfpenny, A.M.; Moore, S.R. Applications of molecular neuro-oncology-a review of diffuse glioma integrated diagnosis and emerging molecular entities. Diagn. Pathol., 2019, 14(1), 29.
[http://dx.doi.org/10.1186/s13000-019-0802-8] [PMID: 30967140]
[12]
Molinaro, A.M.; Taylor, J.W.; Wiencke, J.K.; Wrensch, M.R. Genetic and molecular epidemiology of adult diffuse glioma. Nat. Rev. Neurol., 2019, 15(7), 405-417.
[http://dx.doi.org/10.1038/s41582-019-0220-2] [PMID: 31227792]
[13]
Forner, A.; Reig, M.; Bruix, J. Hepatocellular carcinoma. Lancet, 2018, 391(10127), 1301-1314.
[http://dx.doi.org/10.1016/S0140-6736(18)30010-2] [PMID: 29307467]
[14]
Kujawa, K.A.; Lisowska, K.M. Ovarian cancer--from biology to clinic. Postepy Hig. Med. Dosw., 2015, 69, 1275-1290.
[http://dx.doi.org/10.5604/17322693.1184451]
[15]
Penny, S.M. Ovarian cancer: An overview. Radiol. Technol., 2020, 91(6), 561-575.
[PMID: 32606233]
[16]
Kolenda, T.; Guglas, K.; Kopczyńska, M.; Sobocińska, J.; Teresiak, A.; Bliźniak, R.; Lamperska, K. Good or not good: Role of miR-18a in cancer biology. Rep. Pract. Oncol. Radiother., 2020, 25(5), 808-819.
[http://dx.doi.org/10.1016/j.rpor.2020.07.006] [PMID: 32884453]
[17]
Wu, Y.; Wang, T.; Xia, L.; Zhang, M. LncRNA WDFY3-AS2 promotes cisplatin resistance and the cancer stem cell in ovarian cancer by regulating hsa-miR-139-5p/SDC4 axis. Cancer Cell Int., 2021, 21(1), 284.
[http://dx.doi.org/10.1186/s12935-021-01993-x] [PMID: 34051810]
[18]
Hou, X.; Wen, J.; Ren, Z.; Zhang, G. Non-coding RNAs: New biomarkers and therapeutic targets for esophageal cancer. Oncotarget, 2017, 8(26), 43571-43578.
[http://dx.doi.org/10.18632/oncotarget.16721] [PMID: 28388588]
[19]
Kato, H.; Nakajima, M. Treatments for esophageal cancer: A review. Gen. Thorac. Cardiovasc. Surg., 2013, 61(6), 330-335.
[http://dx.doi.org/10.1007/s11748-013-0246-0] [PMID: 23568356]
[20]
Kong, Q.; Li, G.; Yin, G.; Li, K.; Zhang, D.; Xu, W.; Long Noncoding, R.N.A. Long noncoding RNA WDFY3-AS2 represses the progression of esophageal cancer through miR-18a/PTEN axis. J. Oncol., 2021, 2021, 1-12.
[http://dx.doi.org/10.1155/2021/9951010] [PMID: 34194502]
[21]
Zhang, Y.; Narayanan, S.P.; Mannan, R.; Raskind, G.; Wang, X.; Vats, P.; Su, F.; Hosseini, N.; Cao, X.; Kumar-Sinha, C.; Ellison, S.J.; Giordano, T.J.; Morgan, T.M.; Pitchiaya, S.; Alva, A.; Mehra, R.; Cieslik, M.; Dhanasekaran, S.M.; Chinnaiyan, A.M. Single-cell analyses of renal cell cancers reveal insights into tumor microenvironment, cell of origin, and therapy response. Proc. Natl. Acad. Sci. USA, 2021, 118(24), e2103240118.
[http://dx.doi.org/10.1073/pnas.2103240118] [PMID: 34099557]
[22]
Abnet, C.C.; Arnold, M.; Wei, W.Q. Epidemiology of esophageal squamous cell carcinoma. Gastroenterology, 2018, 154(2), 360-373.
[http://dx.doi.org/10.1053/j.gastro.2017.08.023] [PMID: 28823862]
[23]
Ohashi, S.; Miyamoto, S.; Kikuchi, O.; Goto, T.; Amanuma, Y.; Muto, M. Recent advances from basic and clinical studies of esophageal squamous cell carcinoma. Gastroenterology, 2015, 149(7), 1700-1715.
[http://dx.doi.org/10.1053/j.gastro.2015.08.054] [PMID: 26376349]
[24]
Deng, H.Y.; Wang, Y.C.; Ni, P.Z.; Lin, Y.D.; Chen, L.Q. Long noncoding RNAs are novel potential prognostic biomarkers for esophageal squamous cell carcinoma: An overview. J. Thorac. Dis., 2016, 8(8), E653-E659.
[http://dx.doi.org/10.21037/jtd.2016.07.01] [PMID: 27621894]
[25]
Kumar, P.; Aggarwal, R. An overview of triple-negative breast cancer. Arch. Gynecol. Obstet., 2016, 293(2), 247-269.
[http://dx.doi.org/10.1007/s00404-015-3859-y] [PMID: 26341644]
[26]
Srigley, J.R.; Delahunt, B.; Eble, J.N.; Egevad, L.; Epstein, J.I.; Grignon, D.; Hes, O.; Moch, H.; Montironi, R.; Tickoo, S.K.; Zhou, M.; Argani, P.; Panel, I.R.T. The International Society of Urological Pathology (ISUP) Vancouver Classification of Renal Neoplasia. Am. J. Surg. Pathol., 2013, 37(10), 1469-1489.
[http://dx.doi.org/10.1097/PAS.0b013e318299f2d1] [PMID: 24025519]
[27]
Rysz, J.; Franczyk, B.; Ławiński, J.; Gluba-Brzózka, A. Characteristics of clear cell papillary renal cell carcinoma (ccpRCC). Int. J. Mol. Sci., 2021, 23(1), 151.
[http://dx.doi.org/10.3390/ijms23010151] [PMID: 35008576]
[28]
Lambe, G.; Durand, M.; Buckley, A.; Nicholson, S.; McDermott, R. Adenocarcinoma of the lung: From BAC to the future. Insights Imag., 2020, 11(1), 69.
[http://dx.doi.org/10.1186/s13244-020-00875-6] [PMID: 32430670]
[29]
Finberg, K.E.; Sequist, L.V.; Joshi, V.A.; Muzikansky, A.; Miller, J.M.; Han, M.; Beheshti, J.; Chirieac, L.R.; Mark, E.J.; Iafrate, A.J. Mucinous differentiation correlates with absence of EGFR mutation and presence of KRAS mutation in lung adenocarcinomas with bronchioloalveolar features. J. Mol. Diagn., 2007, 9(3), 320-326.
[http://dx.doi.org/10.2353/jmoldx.2007.060182] [PMID: 17591931]

Rights & Permissions Print Cite
Article Metrics
3
© 2024 Bentham Science Publishers | Privacy Policy